Sure — this is one of the most active (and controversial) areas in pain research right now.
Researchers are trying to find measurable signals that track pain-related processes without relying on self-report, typically from:
- Neuroimaging: fMRI, structural MRI, PET
- Neurophysiology: EEG/MEG
- Peripheral physiology: autonomic signals (HRV, skin conductance), pupillometry
- Molecular markers: inflammatory mediators, neuroimmune signals (still very exploratory)
A key nuance: many candidates measure nociception / threat / arousal more than the conscious experience of pain.
One landmark result is the fMRI-based Neurologic Pain Signature, a multivariate brain activation pattern that predicts experimentally-evoked physical pain intensity better than single-region measures. citeturn0search0
- Detect group-level differences well (e.g., “condition A tends to show more NPS than condition B”)
- Track changes when stimulus intensity changes (lab pain)
- Sometimes show modulation with interventions in controlled settings
Even strong signatures face major limits:
- Specificity: overlapping brain patterns can reflect salience, attention, stress, emotion, or expectation—not pain alone.
- Generalizability: models trained on healthy volunteers with heat/electric pain may not transfer to diverse clinical pain states.
- Individual inference is risky: you can’t reliably scan one person and conclude “they are/aren’t in pain” at a clinically acceptable error rate across contexts (a point emphasized in critical reviews and pain societies’ commentary). citeturn0search11turn0search19
There’s also an active discussion inside the pain field about why self-report remains central and what brain biomarkers can realistically add. citeturn0search3
EEG is attractive because it’s cheap, portable, repeatable, and has millisecond resolution.
What’s being studied:
- Spectral power changes (alpha/beta/gamma)
- Connectivity patterns
- Complexity measures (e.g., fractal dimension)
- Machine learning models that map EEG features → pain severity or risk
Recent work includes attempts at wearable EEG + ML for chronic pain intensity estimation and studies testing whether EEG markers generalize across datasets. citeturn0search5turn0search9turn0search13
Main barriers:
- EEG signals are easily confounded by sleepiness, drugs (opioids/sedatives), anxiety, movement, artifacts
- Many models work in small datasets and can fail when moved to new populations (the “generalization” problem)
PET can probe neuroinflammation, opioid receptor activity, neurotransmitters, etc. This may be useful to identify pain mechanisms (e.g., central sensitization-like patterns) and stratify patients, but it’s expensive and still not a direct readout of subjective pain.
(If you want, we can go deeper on specific PET targets like TSPO for glial activation, μ-opioid receptor binding, etc.)
In anesthesia/ICU, devices combine autonomic signals into indices to guide analgesia (e.g., ANI, SPI, NOL, pupillometry). They can be useful when the patient can’t report, but they mainly reflect nociceptive/autonomic balance, and are influenced by many non-pain factors. citeturn0search10turn0search6turn0search2
Think of these as “how hard the body is reacting” more than “how much it hurts.”
The most realistic near-term clinical value is not a universal “objective pain score,” but:
- Mechanism-based subtyping (who is more likely neuropathic vs inflammatory vs centralized, etc.)
- Predicting treatment response (who benefits from drug A vs therapy B)
- Risk prediction (who may transition from acute to chronic pain)
- Adjunct assessment in non-communicative patients (supporting, not replacing, behavioral scales)
Which setting are you thinking about?
- Acute post-op / ICU / anesthesia
- Chronic pain clinic (e.g., fibromyalgia, low back pain, neuropathic pain)
- Medico-legal / disability evaluation
- Pediatrics / dementia / non-verbal patients
Each has a different “best” research direction and different ethical stakes.